Vertex Pharmaceuticals Incorporated (BVMF:VRTX34)

Market Cap	632.90B -5.6%
Revenue (ttm)	62.48B +10.3%
Net Income	19.59B
EPS	75.80
Shares Out	n/a
PE Ratio	32.31
Forward PE	23.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	781
Open	618.38
Previous Close	618.38
Day's Range	618.38 - 618.38
52-Week Range	497.63 - 735.49
Beta	0.32
RSI	51.69
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: VRTX34

Financial Performance

Financial numbers in USD